Genetics of Anthracycline-Associated Cardiotoxicity
Anthracyclines are a major component of chemotherapies used in many pediatric and adult malignancies. Anthracycline-associated cardiotoxicity (ACT) is a dose-dependent adverse effect that has substantial impact on morbidity and mortality. Therefore, the identification of genetic variants associated...
Main Authors: | Talal Khalid Al-Otaibi, Benjamin Weitzman, Usman A. Tahir, Aarti Asnani |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-04-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2022.867873/full |
Similar Items
-
Novel Therapeutics for Anthracycline Induced Cardiotoxicity
by: Jacqueline T. Vuong, et al.
Published: (2022-04-01) -
Predictive Factors of Therapy-Related Cardiovascular Events in Patients with Lymphoma Receiving Anthracyclines
by: Alberto Lopez-Garcia, et al.
Published: (2024-04-01) -
Exercise Cardio-Oncology: Exercise as a Potential Therapeutic Modality in the Management of Anthracycline-Induced Cardiotoxicity
by: Dong-Woo Kang, et al.
Published: (2022-01-01) -
Genetic basis of anthracyclines cardiotoxicity: Literature review
by: M. Yu. Sinitsky, et al.
Published: (2021-10-01) -
Dexrazoxane in anthracycline cardiotoxicity
by: Abhijit S Nair
Published: (2017-01-01)